51294-23-6

Basic information

• Product Name: 2-isopropyl-1H-imidazole-4,5-dicarboxylic acid
• Synonyms: 2-isopropyl-1H-imidazole-4,5-dicarboxylic acid
• CAS NO: 51294-23-6
• Molecular Weight: 198.178
• Mol File: 51294-23-6.mol
• Article Data: 4

Chemical Properties

• Melting Point: 231 °C (decomp)
• Boiling Point: 530.2±35.0 °C(Predicted)
• Density: 1.456±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-isopropyl-1H-imidazole-4,5-dicarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-isopropyl-1H-imidazole-4,5-dicarboxylic acid(51294-23-6)
• EPA Substance Registry System: 2-isopropyl-1H-imidazole-4,5-dicarboxylic acid(51294-23-6)

Safety Data

• Hazardous Substances Data: 51294-23-6(Hazardous Substances Data)

Upstream product

• 5851-43-4 2-isopropylbenzimidazole 
• 78-84-2 isobutyraldehyde 
• 13171-63-6 L_g-tartaric acid-dinitrate 

Downstream Products

• 36947-68-9 2-isopropylimidazole 
• 15719-64-9 methylammonium carbonate 
• 76100-35-1 2-Isopropyl-1-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)imidazol-4,5-dicarbonsaeure-dimethylester 

Relevant articles and documents

Luminescent terbium(iii) complex-based titania sensing material for fluoride and its photocatalytic properties

A new terbium 2-isopropylimidazole-4,5-dicarboxylic acid complex was prepared and incorporated into titanium dioxide matrix by mild sol-gel method. Then we fabricated a terbium luminescent hybrid material, which displayed striking green emission even in pure water. It was interesting to find that this target material exhibited highly selective and fast (1 s) quenching effect to F- compared with CH3COO-, Cl-, Br-, I-. We recognized that the hydrogen bonding interactions between fluoride and ligand resulted in the recognition process. More significantly, this hybrid titania material prepared under low temperature (80°C) could be used in photodegradation of methyl orange in aqueous environment.

AMIDO-SUBSTITUTED AZOLE COMPOUNDS

The present invention relates to amido-substituted azole compounds of general formula (I), in which X1, X2, R1, R2, R4, R5, R7 and R8 are as defined in the claims which are inhibitors of TNKS1 and/or TNKS2, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.